-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma patients treated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies eventually relapse or are refractory to these treatments, resulting in a poor prognosis
.
Among refractory patients with tertiary exposures, 31% had a median overall survival of 9.
Multiple myeloma patients treated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies eventually relapse or are refractory to these treatments, resulting in a poor prognosis
CAR-T lymphoma
Specifically, the CHMP recommends Carvykti for the treatment of adults with relapsed/refractory (r/r) multiple myeloma who have received at least three prior therapies, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies
.
The CHMP support is supported by the results of the phase Ib/II CARTITUDE-1 study, which showed that patients in the Carvykti arm produced an overall response rate of 97% and a strict response rate of 67% after approximately one year of follow-up
The CHMP support is supported by the results of the phase Ib/II CARTITUDE-1 study, which showed that patients in the Carvykti arm produced an overall response rate of 97% and a strict response rate of 67% after approximately one year of follow-up
Figure 1.
Patient PFS
Patient's PFSFigure 1.
Patient's PFSFigure 1.
Patient's PFS
This single-arm, open-label, Phase Ib/II study (CARTITUDE-1) at 16 U.
S.
centers enrolled patients 18 years of age or older with a diagnosis of multiple myeloma and an ECOG PS of 0-1 , they received 3 or more prior lines of therapy
.
A single infusion of Carvykti (target dose of 0.
Diagnosis 6
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5533481 https://firstwordpharma.
com/story/5533481 Leave a comment here